CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Study sponsor: Palvella Therapeutics, Inc. · PVLA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-03-13Actual
Enrollment · participants73Actual
Source updated2024-08-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.